Looks like you’re on the UK site. Choose another location to see content specific to your location
NICE guidance recommends paracetamol over antibiotics for sore throats
GPs and other healthcare professionals are being advised against prescribing antibiotics for people with sore throats.
Final guidance from the National Institute for Health and Care Excellence (NICE) and Public Health England has recommended that pain relief such as paracetamol or ibuprofen are preferable to antibiotics for the vast majority of patients experiencing a sore throat.
Respiratory tract infections are one of the main reasons people visit their GP or pharmacist. Although most people will recover from their sore throat without antibiotics after around a week, antibiotics are currently prescribed in 60 percent of cases.
This is a cause for concern at a time when the overall effectiveness of antibiotics is waning due to the development of antibiotic-resistant superbugs, the emergence of which has been seen as a major public health emergency.
Professor Gillian Leng, deputy chief executive at NICE, said: "We are living in a world where bacteria are becoming resistant to antibiotics. It is vital these medicines are protected, and only used when they are effective."
The guidance also noted that people whose sore throat is caused by bacteria – a condition sometimes referred to as strep-throat – may be more likely to benefit from antibiotics, and that healthcare professionals should use validated symptom scoring tools to identify these patients.
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard